Could Orforglipron Change Obesity Treatment Forever?

In this Q&A with Pharmacy Times, Richard Frank, MD, chief medical officer at Vida, discusses how emerging oral GLP-1 therapies may shift the obesity treatment landscape by offering a more convenient alternative to injectables, potentially improving patient adherence and earlier initiation of care. He highlights key differences in efficacy, tolerability, and real-world use, while emphasizing the importance of individualized treatment selection. Frank also explores how expanded therapeutic options could enhance access and flexibility for patients and providers.